Endophthalmitis Clinical Trial
Official title:
Antibiotic Prophylaxis for Cataract Surgery Version 7e January 22 2003
Cataract is the most important cause of visual impairment and decreased mobility in the
elderly. While surgery is usually successful, it is also responsible for permanent loss of
vision in up to 0.1% of patients due to severe post-operative infection (endophthalmitis).
Because of this risk, surgery is typically performed on one eye at a time leaving the
patient with a monocular cataract causing considerable visual impairment with reduction in
mobility and quality of life. A second operation is required which often takes place up to
one year later.
It is not known at present whether the post-operative complication of endophthalmitis can be
prevented by perioperative use of antibiotics. This randomised study (masked and
placebo-controlled for topical levofloxacin and unmasked for intracameral injection of
cefuroxime) sets out to test in 4 groups, each of 8,750 cataract surgery patients, if either
topical antibiotic (levofloxacin) perioperatively or an intraocular (intracameral) injection
of antibiotic (cefuroxime) at the end of phacoemulsification cataract surgery or the
combination provides effective prophylaxis of post-operative infection (endophthalmitis)
compared to controls in whom perioperative antibiotics are not used. The result will provide
a scientific basis for prophylaxis of infection (endophthalmitis) following cataract surgery
in Europe as well as an accurate figure for the incidence of endophthalmitis following
phacoemulsification cataract surgery in Europe for the first time.
Cataract extraction with intra-ocular lens implantation is the most commonly performed
surgical procedure in the elderly population in Europe. The frequency varies in different
European Union (EU) countries involving 2 to 7 per 1000 population per annum. A population
with an ever-increasing proportion of the elderly is advancing this figure with numbers
requiring surgery expected to increase by 70% by 2006. While technical advances
(phacoemulsification) have enhanced the efficacy of the procedure, the possibility of
serious post-operative infection with loss of vision remains the most important unsolved
problem.
In the absence of scientific evidence, the European Society of Cataract and Refractive
Surgeons (ESCRS) wishes to determine whether one currently developed method of delivering
antibiotics intraocularly in Sweden is of benefit compared to surgery without the use of
perioperative antibiotics, as currently practised in many European centres, or to the use of
frequent application of topical antibiotic drops perioperatively. The ESCRS also wishes to
assess possible risk factors for later endophthalmitis.
This study requires four groups of 8,750 patients - 35,000 in all - to demonstrate
reductions of currently reported rates of endophthalmitis (approximately 0.3%) in patients
where no intraocular antibiotics are used, or where they are used by the subconjunctival
route. Other studies using intraocular vancomycin have reported results as low as 0.05%, but
these studies were not standardised or controlled and the results were anecdotal. In
addition, vancomycin should not be used for routine prophylaxis and should only be used as
the antibiotic of 'last resort'.
This multi-centre randomised study involves 24 operating units in 8 EU countries (Austria,
Belgium, England, Germany, Italy, Poland, Portugal and Spain) and Turkey. Results in 8,750
patients receiving an intracameral injection of antibiotic (cefuroxime) at the end of
surgery will be compared to 8,750 patients receiving topical antibiotic (levofloxacin)
prophylaxis before and at the end of surgery, 8,750 patients receiving the combination and
8,750 patients receiving neither regime; in addition, all patients will receive povidone
iodine antiseptic prophylaxis prior to surgery and post-operative levofloxacin from days 1
to 6 to prevent wound infection.
This group size will be sufficiently large to ensure at least 80% statistical power to
detect a reduction of incidence from 0.25% to 0.08% using 5% significance level tests.
Surgical data from all patients will be collected directly into computers based within each
operating theatre and transmitted to a central server in Glasgow (University of
Strathclyde). Follow-up data for the presence or absence of endophthalmitis will be
collected from all patients at post-operative visits and similarly recorded on computers for
transmission to the central server. Sophisticated techniques will be used to check all data
as it is uploaded.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04214821 -
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
|
Phase 1/Phase 2 | |
Completed |
NCT00461656 -
Povidone-iodine Antisepsis for Strabismus Surgery
|
Phase 4 | |
Completed |
NCT04568213 -
Hypochlorous Acid Disinfection Prior to Cataract Surgery
|
Phase 3 | |
Terminated |
NCT01496794 -
Endophthalmitis Cultures
|
N/A | |
Completed |
NCT00406913 -
Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery
|
N/A | |
Recruiting |
NCT05079854 -
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis
|
Phase 4 | |
Recruiting |
NCT05432336 -
Complex Ocular Infection, Optimization of Microbiological Diagnosis
|
||
Recruiting |
NCT02810587 -
Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics
|
N/A | |
Completed |
NCT00398658 -
Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis
|
Phase 4 | |
Recruiting |
NCT04035369 -
Endophthalmitis Post Intravitreal Injections
|
N/A | |
Not yet recruiting |
NCT03420820 -
Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection
|
N/A | |
Recruiting |
NCT06268561 -
Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
|
||
Withdrawn |
NCT00335231 -
Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery
|
N/A | |
Not yet recruiting |
NCT03244072 -
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
|
Phase 2/Phase 3 | |
Completed |
NCT01323868 -
Endogenous Endophthalmitis in the Inpatient Setting
|
N/A | |
Completed |
NCT03363295 -
Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis
|
Phase 4 | |
Suspended |
NCT02590523 -
Intracameral Antibiotic Safety Study
|
Phase 3 | |
Terminated |
NCT02770729 -
Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.
|
Phase 3 | |
Not yet recruiting |
NCT02324166 -
Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain
|
Phase 4 | |
Completed |
NCT02595359 -
Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis
|
Phase 2 |